USPH Stock Analysis: U.S. Physical Therapy | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.137m USD | 12M Return: 4.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.1M
EPS Trend: 14.2%
Qual. Beats: 0
Rev. Trend: 95.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
U.S. Physical Therapy, Inc. (USPH) operates and manages outpatient physical therapy clinics across the United States, operating through two reportable segments: Physical Therapy Operations and Industrial Injury Prevention Services.
The Physical Therapy Operations segment delivers pre- and post-operative care, orthopedic rehabilitation, sports injury treatment, preventative care, workers compensation rehabilitation, and neurological injury treatment to patients in a clinic-based outpatient setting.
The Industrial Injury Prevention Services segment contracts with large employers-including Fortune 500 companies, insurers, and their contractors-to provide onsite injury prevention, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments, delivered by physical therapists and certified athletic trainers.
Listed on the NYSE and classified within the GICS Health Care Facilities sub-industry, USPH represents a small-cap healthcare services provider, headquartered in Houston, Texas, with its founding year traced to 1990. The outpatient rehabilitation model relies on referral-based patient volumes from physicians, employers, and insurance carriers, while the industrial segment generates revenue through direct employer contracts.
- Industrial Injury Prevention segment outpaces core clinic growth
- Patient visit volumes soften on weaker elective procedure referrals
- Rising therapist wages and labor costs pressure operating margins
| Net Income: 1.18m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.63 > 1.0 |
| NWC/Revenue: 2.99% < 20% (prev 3.23%; Δ -0.24% < -1%) |
| CFO/TA 0.07 > 3% & CFO 83.7m > Net Income 1.18m |
| Net Debt (492.4m) to EBITDA (103.5m): 4.76 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.2m) vs 12m ago 0.23% < -2% |
| Gross Margin: 20.44% > 18% (prev 19.12%; Δ 1.32% > 0.5%) |
| Asset Turnover: 60.22% > 50% (prev 56.64%; Δ 3.58% > 0%) |
| Interest Coverage Ratio: 8.13 > 6 (EBIT TTM 81.0m / Interest Expense TTM 9.97m) |
| A: 0.02 (Total Current Assets 139.1m - Total Current Liabilities 117.3m) / Total Assets 1.24b |
| B: 0.17 (Retained Earnings 216.9m / Total Assets 1.24b) |
| C: 0.07 (EBIT TTM 81.0m / Avg Total Assets 1.21b) |
| D: 1.02 (Book Value of Equity 469.0m / Total Liabilities 459.2m) |
| Altman-Z'' = 2.21 = BBB |
| DSRI: 0.98 (Receivables 96.7m/90.9m, Revenue 729.2m/668.2m) |
| GMI: 0.94 (GM 19.12% / 20.44%) |
| AQI: 1.00 (AQ_t 0.74 / AQ_t-1 0.74) |
| SGI: 1.09 (Revenue 729.2m / 668.2m) |
| TATA: -0.07 (NI 1.18m - CFO 83.7m) / TA 1.24b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at USD 76.64 with a total of 156,674 shares traded. Over the past week, the price has changed by +2.98%, over one month by +11.36%, over three months by +5.49% and over the past year by +4.31%.
Current recommended Stop Loss: 73.10 (which is 4.6% or 1.3 ATR below the current price).
U.S. Physical Therapy has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy USPH.
- StrongBuy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 93.7 | 22.2% |
P/E Trailing = 149.48
P/E Forward = 27.027
P/S = 1.444
P/B = 2.415
P/EG = 2.7062
Revenue TTM = 729.2m USD
EBIT TTM = 81.0m USD
EBITDA TTM = 103.5m USD
Long Term Debt = 194.0m USD (from longTermDebt, last quarter)
Short Term Debt = 53.6m USD (from shortTermDebt, last quarter)
Debt = 520.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 158.0m
Net Debt = 492.4m USD (calculated: Debt 520.8m - CCE 28.4m)
Enterprise Value = 1.63b USD (1.14b + Debt 520.8m - CCE 28.4m)
Interest Coverage Ratio = 8.13 (Ebit TTM 81.0m / Interest Expense TTM 9.97m)
EV/FCF = 24.37x (Enterprise Value 1.63b / FCF TTM 66.9m)
FCF Yield = 4.10% (FCF TTM 66.9m / Enterprise Value 1.63b)
FCF Margin = 9.17% (FCF TTM 66.9m / Revenue TTM 729.2m)
Net Margin = 0.16% (Net Income TTM 1.18m / Revenue TTM 729.2m)
Gross Margin = 20.44% ((Revenue TTM 729.2m - Cost of Revenue TTM 580.2m) / Revenue TTM)
Gross Margin QoQ = 14.47% (prev 20.65%)
Tobins Q-Ratio = 1.31 (Enterprise Value 1.63b / Total Assets 1.24b)
Interest Expense / Debt = 1.91% (Interest Expense 9.97m / Debt 520.8m)
Taxrate = 25.83% (18.4m / 71.0m)
NOPAT = 60.1m (EBIT 81.0m * (1 - 25.83%))
Current Ratio = 1.19 (Total Current Assets 139.1m / Total Current Liabilities 117.3m)
Debt / Equity = 1.11 (Debt 520.8m / totalStockholderEquity, last quarter 469.0m)
Debt / EBITDA = 4.76 (Net Debt 492.4m / EBITDA 103.5m)
Debt / FCF = 7.36 (Net Debt 492.4m / FCF TTM 66.9m)
Total Stockholder Equity = 487.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.10% (Net Income 1.18m / Total Assets 1.24b)
RoE = 0.24% (Net Income TTM 1.18m / Total Stockholder Equity 487.4m)
RoCE = 11.89% (EBIT 81.0m / Capital Employed (Equity 487.4m + L.T.Debt 194.0m))
RoIC = 5.23% (NOPAT 60.1m / Invested Capital 1.15b)
WACC = 6.37% (E(1.14b)/V(1.66b) * Re(8.64%) + D(520.8m)/V(1.66b) * Rd(1.91%) * (1-Tc(0.26)))
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.38 | Cagr: 0.53%
[DCF] Terminal Value 77.97% ; FCFF base≈62.6m ; Y1≈71.7m ; Y5≈105.5m
[DCF] Fair Price = 72.00 (EV 1.59b - Net Debt 492.4m = Equity 1.10b / Shares 15.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 14.17 | EPS CAGR: 0.41% | SUE: -0.67 | # QB: 0
Revenue Correlation: 95.87 | Revenue CAGR: 7.36% | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.85 | Chg30d=+4.31% | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.80 | Chg30d=+1.63% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=2.93 | Chg30d=+4.20% | Revisions=+0% | GrowthEPS=+11.2% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=3.41 | Chg30d=+0.01% | Revisions=+0% | GrowthEPS=+16.7% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: +0% (up=0, down=0)